View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
November 6, 2018updated 11 Jul 2022 9:55am

Waste not, want not: how exosomes went from trash to trials

Exosomes are cell-derived vesicles that are present in almost all eukaryotic fluids, including blood, urine, cerebrospinal fluid (CSF) and cultured medium of cell cultures in vitro.

By GBI Research

Exosomes are cell-derived vesicles that are present in almost all eukaryotic fluids, including blood, urine, cerebrospinal fluid (CSF) and cultured medium of cell cultures in vitro.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Exosomes are vesicular components of a host cell, formed from the fusion of an internal multivesicular body (intracellular endocytic compartment) with the plasma membrane, releasing the internal vesicles into the surrounding milieu.

First discovered around 50 years ago, exosomes were considered as a means of cellular waste disposal and for a long time they were largely ignored, forgotten or dismissed by the scientific community.

However, they are now known to be involved in many key biological processes including inflammation, angiogenesis and coagulation.

Surge in R&D investment in recent years

It is only in the past ten years or so that exosome research has picked up, with a ten-fold increase in the number of publications relating to exosomes between 2006 and 2017.

These vesicles are now being investigated in a variety of applications, including as therapeutic biomarkers, drug delivery systems and therapies in their own right.

The number of clinical trials investigating exosome technologies has rapidly increased in recent years and more than 20 products are currently in active development across a number of therapy areas, including oncology, central nervous system, cardiovascular disease and infectious disease.

Unique properties generate interest

Research within this area remains in the nascent stages with much still to be discovered.

Nonetheless, it represents a promising new field, largely owing to a number of unique properties of exosomes.

For example, exosomes can be engineered to incorporate targeting ligands, allowing them to deliver cargo selectively to cells.

Their small size (30–120nm) allows them to penetrate the blood-brain barrier for the delivery of central nervous system therapies, whereas in cancer they can accumulate within a tumour via the enhanced permeability and retention effects.

Exosomes can also be used as diagnostic tools because they are carriers of the molecular markers of many diseases.

Related GBI report. For more insight and data, visit the GBI Research report store.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology